Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.6.2917

Association between the TP53BP1 rs2602141 A/C Polymorphism and Cancer Risk: A Systematic Review and Meta-Analysis  

Liu, Lei (Department of Ophthalmology, The First Affiliated Hospital, China Medical University)
Zhang, Dong (Department of General Surgery, the Fourth People's Hospital of Shenyang)
Jiao, Jing-Hua (Department of Anesthesiology, Fengtian Hospital, Shenyang Medical College)
Wang, Yu (Department of Development and Planning Office, School of Public Health, China Medical University)
Wu, Jing-Yang (Department of Ophthalmology, The First Affiliated Hospital, China Medical University)
Huang, De-Sheng (Department of Epidemiology, School of Public Health, China Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.6, 2014 , pp. 2917-2922 More about this Journal
Abstract
Background: The p53-binding protein 1 (TP53BP1) gene may be involved in the development of cancer through disrupting DNA repair. However, investigation of associations between TP53BP1 rs2602141 A/C polymorphism and cancer have yielded contradictory and inconclusive outcomes. We therefore performed a meta-analysis to evaluate the association between the TP53BP1 rs2602141 A/C polymorphism and cancer susceptibility. Materials and Methods: Published literature from PubMed, Medline, the Cochrane Library, EMbase, Web of Science, Google (scholar), CBMDisc, Chongqing VIP database, and CNKI database were retrieved. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed or random-effects models. Publication bias was estimated using funnel plots, Begg's and Egger's test. Results: A total of seven studies (3,018 cases and 5,548 controls) were included in the meta-analysis. Our results showed that the genotype distribution of TP53BP1 rs2602141 A/C was not associated with cancer risk overall. However, on subgroup analysis, we found that TP53BP1 rs2602141 A/C was associated with cancer risk within an allele model (A vs C, OR=1.14, 95%CI: 1.01-1.29) and a codominant model (AA vs CC, OR=1.36, 95%CI: 1.06-1.74) in Asians rather than in Caucasians. Subgroup analysis by cancer type, genotype, and with or without adjustment for controls showed no significant association. Conclusions: The findings suggested an association between rs2602141 A/C polymorphism in TP53BP1 gene and increased risk of cancer in Asians.
Keywords
TP53-binding protein 1; cancer; polymorphism; gene; meta-analysis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Williams RS, Green R, Glover JN (2001). Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol, 8, 838-42.   DOI   ScienceOn
2 Zhang H, Hao S, Zhao J, et al (2013). Common Genetic Variants in 53BP1 Associated with Non-small Cell Lung Cancer Risk in Han Chinese. Arch Med Res, 45, 84-9.
3 Zhao L, Zhao X, Wu X, Tang W (2013). Association of p53 Arg72Pro polymorphism with esophageal cancer: a meta-analysis based on 14 case-control studies. Genet Test Mol Biomarkers, 17, 721-6.   DOI   ScienceOn
4 Miwa S, Tome Y, Yano S, et al (2013). Single cell time-lapse imaging of focus formation by the DNA damage-response protein 53BP1 after UVC irradiation of human pancreatic cancer cells. Anticancer Res, 33, 1373-7.
5 Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 1000097.   DOI   ScienceOn
6 Ma H, Hu Z, Zhai X, et al (2006). Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis, 27, 766-71.
7 Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
8 Naidu R, Har YC, Taib NA (2011). Genetic polymorphisms of TP53-binding protein 1 (TP53BP1) gene and association with breast cancer risk. APMIS, 119, 460-7.   DOI   ScienceOn
9 Rappold I, Iwabuchi K, Date T, Chen J (2001). Tumor suppress or p53 binding protein1 (53BP1) is involved in DNA damagesignaling pathways. J Cell Biol, 153, 613-20.   DOI   ScienceOn
10 Rauch T, Zhong X, Pfeifer GP, Xu X (2005). 53BP1 is a Positive Regulator of the BRCA1 Promoter. Cell Cycle, 4, 1078-83.
11 Rudd MF, Webb EL, Matakidou A, et al (2006). Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res, 16, 693-701.   DOI   ScienceOn
12 DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.   DOI   ScienceOn
13 Camargo MC, Mera R, Correa P, et al (2006). Interleukin-1 beta and interleukin-1 receptor antagonistgene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15, 1674-87.   DOI   ScienceOn
14 Chen K, Hu Z, Wang LE, et al (2007). Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin Cancer Res, 13, 4300-5.   DOI   ScienceOn
15 DerSimonian R, Kacker R (2007). Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials, 28, 105-14.   DOI   ScienceOn
16 Egger M, Davey SG, Schneider M, et al (1997). Bias in metaanalysis detected by a simple, graphical test. BMJ, 315, 629-34.   DOI   ScienceOn
17 Ferlay J, Shin HR, Bray F, et al (2010). Estimates of world wide burden of cancer in 2008 : GLOBO CAN 2008. Int J Cancer, 127, 2893-917.   DOI   ScienceOn
18 Frank B, Hemminki K, Bermejo JL, et al (2005). TP53-binding protein variants and breast cancer risk: a case-control study. Breast Cancer Res, 7, 502-5.   DOI   ScienceOn
19 Gao LB, Pan XM, Li LJ, et al (2011). RAD 51135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat, 125, 827-35.   DOI
20 He C, Nan H, Qureshi AA, Han J (2010). Genetic variants in the 53BP1 gene and skin cancer risk. J Invest Dermatol, 130, 2850-3.   DOI   ScienceOn
21 Liu GY, Jiang DK, Shen SQ, Yu L (2011). MDM2 SNP309T.>G polymorphism with hepatocellular carcinoma risk: a metaanalysis. Arch Med Res, 42, 149-55.   DOI   ScienceOn
22 Wang B, Matsuoka S, Carpenter PB, Elledge SJ (2002). 53BP1, a mediator of the DNA damage checkpoint. Science, 298, 1435-8.   DOI   ScienceOn
23 Weng Y, Lu L, Yuan G, et al (2012). p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. PLoS One, 7, 45820.   DOI
24 Schultz LB, Chehab NH, Malikzay A, Halazonetis TD (2000). p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol, 151, 1381-90.   DOI   ScienceOn
25 Truong T, Sauter W, Mc Kay JD, et al (2010). International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants. Carcinogenesis, 31, 625-33.   DOI   ScienceOn
26 DiTullio RA Jr, Mochan TA, Venere M, et al (2002). P53BP 1 functions in an ATM dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol, 4, 998-1002.   DOI   ScienceOn